Targeting therapy in pediatric inflammatory bowel disease

Current Treatment Options in Gastroenterology

Volumn 7, Issue 5, 2004, Pages 391-405

  Dubinsky, Maria C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AMINOSALICYLIC ACID DERIVATIVE; ARACHIDONIC ACID; BALSALAZIDE; BUDESONIDE; CIPROFLOXACIN; CYCLOSPORIN; DIGOXIN; FLUCONAZOLE; FOLIC ACID; GLIBENCLAMIDE; INDINAVIR; IRON; KETOCONAZOLE; LITHIUM; MAGNESIUM HYDROXIDE; MESALAZINE; METRONIDAZOLE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; RIFAMPICIN; RIFAXIMIN; RITONAVIR; SALAZOSULFAPYRIDINE; SAQUINAVIR; SUCRALFATE; TACROLIMUS; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ACNE; ADRENAL SUPPRESSION; AGRANULOCYTOSIS; ALOPECIA; ANKLE EDEMA; ANOREXIA; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; AVASCULAR NECROSIS; CATARACT; CHILD; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; ENTERITIS; FEVER; GLAUCOMA; GLUCOSE INTOLERANCE; HEADACHE; HEMOLYTIC ANEMIA; HIRSUTISM; HUMAN; HYPERADRENOCORTICISM; HYPERGLYCEMIA; HYPERTENSION; IMMUNOMODULATION; INSOMNIA; INTERSTITIAL PNEUMONIA; IRRITABILITY; LEUKOPENIA; LIVER TOXICITY; MOON FACE; MYOPATHY; NAUSEA; NEPHRITIS; NIGHT SWEAT; OLIGOSPERMIA; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PRURITUS; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SIDE EFFECT; SKIN ATROPHY; STOMACH DISEASE; STRIA; TASTE DISORDER; TENDINITIS; THROMBOCYTOPENIA; TUBERCULOSIS; ULCERATIVE COLITIS; URTICARIA; VIRUS REACTIVATION; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

EID: 7944233392     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-004-0052-y     Document Type: Review

References (53)

1. Ursing B, Alm T, Barany F, et al.: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982, 83:550-62.
2. Colombel JF, Lemann M, Cassagnou M, et al.: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999, 94:674-78.
3. Greenbloom SL, Steinhart AH, Greenberg GR: Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998, 12:53-56.
4. Prantera C, Zannoni F, Scribano ML, et al.: An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin Am J Gastroenterol 1996, 91:328-332.
5. Sutherland L, Singleton J, Sessions J, et al.: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991, 32:1071-75.
6. Turunen UM, Farkkila MA, Hakala K, et al.: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998, 115:1072-1078.
7. Gionchetti P, Rizzello F, Venturi A, et al.: Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. European Review for Medical & Pharmacological Sciences 1999, 3:27-30.
8. Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993, 118:540-549.
9. Safdi M, DeMicco M, Sninsky CA: Double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Amer J Gastroenterol 1997, 92: 867-1871.
10. Summers RW, Switz DM, Sessions JT, et al.: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979, 77:847-869.
11. Singleton JW, Hanauer SB, Gitnick GL, et al.: Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993, 104:1293-301.
12. Lochs H, Mayer M, Fleig WE, et al.: Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000, 118:264-273.
13. Camma C, Giunta M, Rosselli M, Cottone M: Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997, 113: 465-73.
14. Croog V, Itzkovitz S, Harpaz N, et al.: The Effect of 5-ASA on progression to colorectal neoplasia in ulcerative colitis. Gastroenterol 2004, 126:A20.
15. Sandborn W, Hanauer SB: Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003, 17:29-42.
16. Hanauer SB: Review articles: drug therapy: inflammatory bowel disease. N Engl J Med 1996, 334:841-848.
17. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121: 55-260.
18. Rutgeerts P, Lofberg R, Malchow H, et al.: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med1994, 331:842-45.
19. Greenberg GR, Feagan BG, Martin F, et al.: Oral budesonide for active Crohn's disease. Canadian inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331:836-41.
20. Hyams JS, Moore RE, Leichtner AM, et al.: Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr 1988, 112: 93-898.
21. Markowitz J, Grancher K, Kohn N: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
22. Cortot A, Colombel JF, Rutgeerts P, et al.: Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut 2001, 48:186-190.
23. Treton X, Bouhnik Y, Maty JY, et al.: Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission under treatment is associated with a high risk of relapse. Gastroenterology 2004, 126:A113.
24. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement For 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118: 05-713.
25. Dubinsky MC, Hassard PV, Seidman EG, et al.: Preliminary Evidence Suggests That 6-MP Metabolite Profiles Provide a Biochemical Explanation for 6-MP resistance in patients with Inflammatory Bowel Disease. Gastroenterology 2002, 122:904-915.
26. Connell WR, Kamm MA, Dickson M, et al.: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease Lancet 1994, 343:1249-1252.
27. Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995, 332: 92-97.
28. Feagan BC, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000, 342:1627-32.
29. Oren R, Arber N, Odes S, et al.: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996, 110:1416-1421.
30. Mack DR, Young R, Kaufman SS, et al.: Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998, 132:830-835.
31. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Eng J Med 1994, 330:1841-1845.
32. Fellermann K, Ludwig D, Stahl M, et al.: Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998, 93:1860-1866.
33. Sandborn WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997, 92: 76-879.
34. Sandborn WJ, Present DH, Isaacs KL, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125:380-388.
35. Feagan BG, McDonald JW, Rochon J, et al.: Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Eng J Med 1994, 330:1846-1851.
36. Treem WR, Cohen J, Davis PM, et al.: Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995, 38:474-479.
37. Bousvaros A, Kirschner BS, Werlin SL, et al.: Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000, 137:794-799.
38. Casson DH, Eltumi M, Tomlin S, et al.: Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000, 47:436-440.
39. Fedorak RN, Gangl A, Elson CO, et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000, 119: 473-1482.
40. Van Montfrans C, Rodriguez Pena MS, et al.: Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology 2002, 123: 865-1876.
41. Sands BE, Bank S, Sninsky CA, et al.: Preliminary evaluation of safety and activity of recombinant human Interleukin 11 in patients with active Crohn's disease.Gastroenterology 1999, 117:58-64.
42. Alsahli M, Jeen TY, Peppercorn MA, et al.: A randomized double-blind, placebo controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following Infliximab therapy. Gastroenterology 2002, 122:A775.
43. Madsen K, Cornish A, Soper P, et al.: Probiotic bacteria enhance murine and human intestinal epithelial barrier function Gastroenterology 2001, 121:580-591.
44. Dieckgraefe BK, Korzenik JR: Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002, 360:1478-1480.
45. Belluzzi A, Brignola C, Campieri M: Effect of an entericcoated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996, 334:1557-1560.
46. Plevy S, Salzberg B, Van Assche P, et al.: A humanized Anti-CD3 monoclonal antibody, Visilizumab, for treatment of severe, steroid refractory ulcerative colitis: Results of Phase 1 Study Gastroenterology 2004, 127:A75.
47. Mannon P, Fuss I, Mayer L, et al.: Anti-interleukin 12 Treats Active Crohn's Disease. Gastroenterology 2004, 127: 22.
48. Lochner M, Forster I: Anti-interleukin-18 therapy in murine models of inflammatory bowel disease. Pathobiology 2002-2003, 70:164-169.
49. Ito H, Takazoe M, Fukuda Y, et al.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004, 126:989-996.
50. Sandborn WJ, Hanauer SB, Loftus EV, et al.: An open label study of the human Anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to Infliximab for Crohn's disease. Gastroenterology 2004, 127:A53.
51. Rutgeerts P, Lemmens L, Van Assche G, et al.: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17: 85-192.
52. Yacyshyn BR, Chey WY, Goff J, et al.: 2302-CS9 Investigators. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002, 51:30-36.
53. Ghosh S, Goldin E, Gordon FH, et al.: Pan-European Study Group. Natalizumab for active Crohn's disease. N Eng J Med 2003, 348:24-32.